SAP30, an oncogenic driver of progression, poor survival, and drug resistance in neuroblastoma.

Mol Ther Nucleic Acids · 2024 · PMC11137595 · PMID 38817681

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As shown in Figure 5 B, progression-specific and MYCN -amplified patient-derived xenograft tumors showed a trend for higher SAP30 expression than diagnosis-specific tumors.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.